Immunotherapy and mRNA are just hope ⚠️ Too early to use in DCIS breast cancer
- Youwanush Kongdan
- Jan 21, 2025
- 2 min read
Updated: May 24
Immunotherapy and mRNA in breast cancer: ready yet?
Immunotherapy and mRNA vaccines are being studied in breast cancer, including DCIS. Although promising, for many indications they remain investigational and it is still too early to use them as general standard care. This article gives a balanced view of where things stand.
Assoc. Prof. Dr. Youwanush Kongdan
Nam Rak Hospital would like to invite everyone to understand the facts about "Using immunotherapy with mRNA", a new technology that is gaining interest for treating early stage DCIS (Ductal Carcinoma in Situ) breast cancer. Although it has potential for treatment , at present it is still too early to be used in practice.
Why shouldn't you use it yet? 🤔
In Investigation : Immunotherapy combined with mRNA for DCIS breast cancer is still in Phase 1 clinical trials to evaluate safety and efficacy.
Study results are unclear : Although some studies have shown positive results, there is not enough data to confirm long-term efficacy and safety.
Risks : Like other cancer treatments, mRNA immunotherapy can have side effects and may not be suitable for all patients.
Case study example 📑
DCIS patients receiving mRNA vaccines : There are case reports of DCIS patients enrolled in an mRNA vaccine study. During the first 2 years, the patients responded well to treatment, but later the cancer recurred and developed into metastatic cancer. This case demonstrates that while mRNA immunotherapy is promising, long-term outcomes are not guaranteed.
DCIS patients with mutations : In some cases, DCIS patients may have cancer cell mutations that make mRNA immunotherapy less effective.
Things to consider ⚠️
Consult a doctor : Before deciding to undergo any treatment, you should consult a specialist to assess the risks and benefits.
Stay informed : Medical technology is constantly evolving, so stay informed about the latest news and advances in breast cancer treatment.
Conclusion
Immunotherapy combined with mRNA is a promising technology and may be a new hope in treating DCIS breast cancer , but at this time it is too early to be practically applied. Namarak Hospital is committed to providing accurate and unbiased information to enable patients to make appropriate treatment decisions.
Frequently Asked Questions (FAQ)
Can immunotherapy treat breast cancer?
In some cases, particularly certain stages of TNBC, but it is not suitable for every subtype and is used by specific medical indication.
Are mRNA vaccines used for breast cancer yet?
They remain investigational for many breast cancer settings and are not yet general standard care; follow ongoing research.
Is immunotherapy used for DCIS?
Currently it is too early; standard DCIS care remains surgery and risk-based adjuvant treatment.
Why be cautious about new treatments?
Sufficient evidence of safety and benefit is needed before routine use; balanced information supports careful decisions.
Who should I ask about new treatment options?
A breast cancer specialist can assess which options are evidence-based and suitable for your case.
Related reading
Disclaimer: This information is for general education only and is not a substitute for personalised medical advice. Please consult a qualified specialist.
Comments